• Clinical Insights: July 20, 2021

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval Rezurock™ (belumosudil) Tablets – New Drug Approval – July 16, 2021 – The Food and Drug Administration approved belumosudil (Rezurock™, Kadmon Pharmaceuticals, LLC), a kinase inhibitor, for adult and… Read more »

  • Clinical Insights: July 13, 2021

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval Padcev™ (enfortumab vedotin-ejfv) – New Drug Approval – July 9, 2021 – The Food and Drug Administration approved enfortumab vedotin-ejfv (Padcev™, Astellas Pharma US, Inc.), a Nectin-4-directed antibody… Read more »

  • Clinical Insights: July 6, 2021

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) Injection – New Drug Approval – June 30, 2021 – Jazz Pharmaceuticals plc announced the U.S. Food and Drug Administration (FDA) approval of… Read more »

  • Clinical Insights: June 29, 2021

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval Verkazia™ (cyclosporine) Ophthalmic Emulsion – New Drug Approval – June 23, 2021 – Santen Pharmaceutical Co., Ltd announced that the U.S. Food and Drug Administration (FDA) has approved… Read more »

  • Connect with Our Experts at the 340B Coalition Summer Conference

    Attending the 340B Coalition Summer Conference July 20-22 and 27-28? Connect with us! Our 340B experts are ready to meet with you, arrange a dashboard analytics demo and discuss our 340B compliance solutions.   Meeting with RxStrategies is easy: –Connect with us throughout the event and visit our virtual booth. –Attend our Vendor Demo on 7/22 from 1:00… Read more »

  • Clinical Insights: June 22, 2021

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval Rezipres® (ephedrine hydrochloride) Injection – New Drug Approval – June 15, 2021 – Eton Pharmaceuticals, Inc announced that the U.S. Food and Drug Administration (FDA) has approved Rezipres®… Read more »

  • Clinical Insights: June 15, 2021

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval Prevnar 20™ (pneumococcal 20-valent conjugate vaccine) Injection – New Vaccine Approval – June 8, 2021 – Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has… Read more »

  • Clinical Insights: June 8, 2021

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval Tembexa™ (brincidofovir) – New Drug Approval – June 4, 2021 – The U.S. Food and Drug Administration approved Tembexa™ (brincidofovir) to treat smallpox. Although the World Health Organization declared… Read more »

  • Clinical Insights: June 1, 2021

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval Lumakras™ (sotorasib) – New Drug Approval – May 28, 2021 – The U.S. Food and Drug Administration approved Lumakras™ (sotorasib) as the first treatment for adult patients with… Read more »

  • Clinical Insights: May 25, 2021

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval Rybrevant™ (amivantamab-vmjw) Injection – New Drug Approval – May 21, 2021 – The U.S. Food and Drug Administration approved Rybrevant™ (amivantamab-vmjw) as the first treatment for adult patients with… Read more »